Exelixis (EXEL) EBITDA Margin Growth (1y) (2011 - 2026)

Exelixis (EXEL) EBITDA Margin Growth (1y) (2011 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 1,552.00
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 1,536.00
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -170.00
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 1,049.00
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Exelixis 14.44 Bn 13.66 Bn 590.86 Mn 751.00

Historic Data

Download Data
DateValue
Apr 3, 2026 751.00
Jan 2, 2026 1,049.00
Oct 3, 2025 1,435.00
Jul 4, 2025 -571.00
Apr 4, 2025 2,671.00
Jan 3, 2025 1,175.00
Sep 27, 2024 2,895.00
Jun 28, 2024 2,673.00
Mar 29, 2024 -12.00
Dec 29, 2023 2,839.00
Sep 29, 2023 -2,379.00
Jun 30, 2023 -339.00
Mar 31, 2023 -1,633.00
Sep 30, 2022 435.00
Jul 1, 2022 -1,198.00
Apr 1, 2022 2,509.00
Oct 1, 2021 3,414.00
Jul 2, 2021 283.00
Apr 2, 2021 -2,498.00
Jan 1, 2021 -2,318.00